Related references
Note: Only part of the references are listed.Homocysteine and Coronary Heart Disease: Meta-analysis of MTHFR Case-Control Studies, Avoiding Publication Bias
Robert Clarke et al.
PLOS MEDICINE (2012)
Homocysteine and Cardiovascular Risk An Old Foe Creeps Back
Arduino A. Mangoni et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2011)
Homocysteine and Reclassification of Cardiovascular Disease Risk
Vikas Veeranna et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2011)
C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20536 patients in the Heart Protection Study
LANCET (2011)
Screening for Future Cardiovascular Disease Using Age Alone Compared with Multiple Risk Factors and Age
Nicholas J. Wald et al.
PLOS ONE (2011)
Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis
J. P. Greving et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Meta-Analysis of Folic Acid Supplementation Trials on Risk of Cardiovascular Disease and Risk Interaction With Baseline Homocysteine Levels
Edgar R. Miller et al.
AMERICAN JOURNAL OF CARDIOLOGY (2010)
Effects of Lowering Homocysteine Levels With B Vitamins on Cardiovascular Disease, Cancer, and Cause-Specific Mortality Meta-analysis of 8 Randomized Trials Involving 37 485 Individuals
Robert Clarke et al.
ARCHIVES OF INTERNAL MEDICINE (2010)
Heart Disease and Stroke Statistics-2009 Update A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee
Donald Lloyd-Jones et al.
CIRCULATION (2009)
Reduced Glomerular Filtration Rate and Its Association with Clinical Outcome in Older Patients at Risk of Vascular Events: Secondary Analysis
Ian Ford et al.
PLOS MEDICINE (2009)
Use of Framinghamrisk score and new biomarkers to predict cardiovascular mortality in older people: population based observational cohort study
Wouter de Ruijter et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Homocysteine Level and Coronary Heart Disease Incidence: A Systematic Review and Meta-analysis
Linda L. Humphrey et al.
MAYO CLINIC PROCEEDINGS (2008)
C-reactive protein and prediction of coronary heart disease and global vascular events in the prospective study of pravastatin in the elderly at risk (PROSPER)
Naveed Sattar et al.
CIRCULATION (2007)
In a population-based prospective study, no association between high blood pressure and mortality after age 85 years
T van Bemmel et al.
JOURNAL OF HYPERTENSION (2006)
Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER)
CJ Packard et al.
CIRCULATION (2005)
Homocysteine and cardiovascular disease: Biological mechanisms, observational epidemliology, and the need for randomized trials
A Splaver et al.
AMERICAN HEART JOURNAL (2004)
Facts and recommendations about total homocysteine determinations: An expert opinion
H Refsum et al.
CLINICAL CHEMISTRY (2004)
Estimation of ten-year risk of fatal cardiovascular disease in Europe:: the SCORE project
RM Conroy et al.
EUROPEAN HEART JOURNAL (2003)
Stabilization of homocysteine in unseparated blood over several days: A solution for epidemiological studies
S Clark et al.
CLINICAL CHEMISTRY (2003)
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial
J Shepherd et al.
LANCET (2002)
Homocysteine and risk of ischemic heart disease and stroke -: A meta-analysis
R Clarke et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Change in blood pressure in the age interval 70-90. Late blood pressure peak related to longer survival
B Lernfelt et al.
BLOOD PRESSURE (2002)
Plasma homocysteine concentration, statin therapy, and the risk of first acute coronary events
PM Ridker et al.
CIRCULATION (2002)
Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study
IJ Schatz et al.
LANCET (2001)
Share Paper
